collaborators

8 papers

stat.ME2026

Adaptive clinical trials based on design-optimal e-values with automatic curtailment: An application to single-arm trials with binary data

Stef Baas, Judith ter Schure, Joost van Rosmalen

The e-value is gaining traction as a robust alternative to p-values and Bayes factors for quantifying statistical evidence. e-values are a promising method for adaptive clinical tr…

stat.ME2025

Thompson, Ulam, or Gauss? Multi-criteria recommendations for posterior probability computation methods in Bayesian response-adaptive trials

Daniel Kaddaj, Stef Baas, Edwin Y. N. Tang +3

Bayesian adaptive designs enable flexible clinical trials by adapting features based on accumulating data. Among these, Bayesian Response-Adaptive Randomization (BRAR) skews patien…

stat.ME2025

Informed Burn-In Decisions in RAR: Harmonizing Adaptivity and Inferential Precision Based on Study Setting

Lukas Pin, Stef Baas, Gianmarco Caruso +2

Response-Adaptive Randomization (RAR) is recognized for its potential to deliver improvements in patient benefit. However, the utility of RAR is contingent on regularization method…

stat.ME2025

Is 1:1 Always Most Powerful? Why Careful Determination of Allocation Ratios Matters in Trial Design

Lukas Pin, Stef Baas, David S. Robertson +1

The principle of allocating an equal number of patients to each arm in a randomized controlled trial remains widely believed to be optimal for maximising statistical power. However…

stat.ME2025

A burn-in(g) question: How long should an initial equal randomization stage be before Bayesian response-adaptive randomization?

Edwin Y. N. Tang, Stef Baas, Daniel Kaddaj +3

Response-adaptive randomization (RAR) can increase participant benefit in clinical trials, but also complicates statistical analysis. The burn-in period (a non-adaptive initial sta…

stat.ME2025

A computational method for type I error rate control in power-maximizing response-adaptive randomization

Stef Baas, Lukas Pin, Sofía S. Villar +1

Maximizing statistical power in experimental design often involves imbalanced treatment allocation, but several challenges hinder its practical adoption: (1) the misconception that…